Short answer: No trials were run with Minivelle itself; the label uses data from Vivelle, to which it is bioequivalent. Common side effects included headache (31.1% on 0.05 mg vs 23.6% on placebo), breast tenderness (12.9% on 0.1 mg vs 0), sinusitis, nasopharyngitis, back pain and bleeding between periods. Minivelle carries the estrogen boxed warning on endometrial cancer, heart and clot risks, probable dementia and breast cancer.
What Minivelle is approved for: Minivelle is a small estrogen patch approved to treat moderate to severe hot flashes (vasomotor symptoms) due to menopause and to prevent postmenopausal osteoporosis (sections 1.1, 1.2). For bone alone, the label says to first consider non-estrogen medicines, and to consider estrogen only for women at significant risk of osteoporosis.
Source
MINIVELLE (estradiol transdermal system) prescribing information, Patient Information and Instructions for Use. Noven Therapeutics. DailyMed, version published August 3, 2026. DailyMed setid 6c5c47ab-28ee-11e1-bfc2-0800200c9a66
WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, and BREAST CANCER
Estrogen-alone therapy: a woman with a uterus who uses estrogen without a progestogen has a higher risk of endometrial cancer; adding a progestogen lowers the risk of endometrial hyperplasia, a possible precursor. Undiagnosed persistent or recurring abnormal genital bleeding after menopause is checked, including with endometrial sampling when indicated. In the Women's Health Initiative (WHI), daily oral conjugated estrogens (CE) 0.625 mg alone raised the risk of stroke and deep vein thrombosis in women 50 to 79 over 7.1 years, and probable dementia in women 65 and older over 5.2 years. Estrogen plus progestin therapy: CE 0.625 mg plus medroxyprogesterone acetate 2.5 mg raised the risk of deep vein thrombosis, pulmonary embolism, stroke, heart attack, invasive breast cancer, and probable dementia in women 65 and older. Neither is to be used to prevent heart disease or dementia. Only those oral doses were studied, so the label says the relevance to other doses, routes or products is not known and the risks cannot be definitively excluded. Estrogens are prescribed at the lowest effective dose for the shortest duration consistent with treatment goals and risks.
These are the label's own numbers from the Adverse Reactions section. Where the label compares with placebo (a dummy treatment), both columns are shown, so you can see how much more often a reaction happened on Minivelle.
| Adverse reaction | 0.025 mg (N=47) | 0.0375 mg (N=130) | 0.05 mg (N=103) | 0.075 mg (N=46) | 0.1 mg (N=132) | Placebo (N=157) |
|---|---|---|---|---|---|---|
| Headache NOS | 7 (14.9) | 35 (26.9) | 32 (31.1) | 23 (50.0) | 34 (25.8) | 37 (23.6) |
| Nasopharyngitis | 3 (6.4) | 16 (12.3) | 10 (9.7) | 9 (19.6) | 11 (8.3) | 24 (15.3) |
| Sinusitis NOS | 4 (8.5) | 17 (13.1) | 13 (12.6) | 3 (6.5) | 7 (5.3) | 16 (10.2) |
| Breast tenderness | 8 (17.0) | 10 (7.7) | 8 (7.8) | 3 (6.5) | 17 (12.9) | 0 |
| Back pain | 4 (8.5) | 10 (7.7) | 9 (8.7) | 4 (8.7) | 14 (10.6) | 10 (6.4) |
| Intermenstrual bleeding | 3 (6.4) | 9 (6.9) | 6 (5.8) | 0 | 14 (10.6) | 7 (4.5) |
| Upper respiratory tract infection NOS | 3 (6.4) | 8 (6.2) | 11 (10.7) | 4 (8.7) | 6 (4.5) | 9 (5.7) |
| Sinus headache | 0 | 12 (9.2) | 5 (4.9) | 5 (10.9) | 2 (1.5) | 8 (5.1) |
| Depression | 5 (10.6) | 4 (3.1) | 7 (6.8) | 0 | 4 (3.0) | 6 (3.8) |
| Dyspepsia | 4 (8.5) | 12 (9.2) | 3 (2.9) | 2 (4.3) | 0 | 10 (6.4) |
| Influenza | 4 (8.5) | 4 (3.1) | 6 (5.8) | 0 | 10 (7.6) | 14 (8.9) |
| Arthralgia | 0 | 11 (8.5) | 4 (3.9) | 2 (4.3) | 5 (3.8) | 9 (5.7) |
| Weight increased | 4 (8.5) | 5 (3.8) | 2 (1.9) | 2 (4.3) | 0 | 3 (1.9) |
| Influenza-like illness | 3 (6.4) | 6 (4.6) | 8 (7.8) | 0 | 3 (2.3) | 10 (6.4) |
Vivelle trial data; Minivelle is bioequivalent to Vivelle. Shown are rows at 8% or more in any group; the full table also lists reactions such as constipation, nausea, anxiety and hot flushes. Values are number of women (percent). Patch strengths are mg of estradiol delivered per day. Application site redness and irritation were 3.2% or less across groups.
In clinical pharmacology studies with Minivelle, 35 percent or less of subjects had barely perceptible redness. No patches were removed due to irritation, and 3 subjects (2.2 percent) reported mild discomfort while wearing Minivelle (N=136).
About 98 percent of 208 Minivelle observations had an adhesion score of 0 (at least 90 percent stuck) over the 84-hour wear period; one woman had a complete detachment. After removal, 54 percent had light adhesive residue and 46 percent had none.
Mean estradiol Cmax after a single patch was 117 pg/mL on 0.1 mg, 56.6 pg/mL on 0.05 mg and 30.3 pg/mL on 0.025 mg per day (Table 2). Estradiol and estrone returned to baseline within 24 hours after removal.
Reported after approval: breast enlargement, palpitations, unstable angina, application site reactions, rash, itching, hives, dizziness, migraine, mood swings, portal vein thrombosis, fatigue, peripheral edema, and swelling of the tongue, lips and throat.
The Warnings and Precautions part of the label lists these. Each line gives the label's heading and what it means in plain words.
Who should not use it. Women with undiagnosed abnormal genital bleeding, current or past breast cancer, estrogen-dependent cancer, current or past DVT, pulmonary embolism, stroke or heart attack, a known anaphylactic reaction, angioedema or allergy to Minivelle, liver impairment or disease, or protein C, protein S or antithrombin deficiency or other clotting disorders.
Blood clots, stroke and heart attack. Estrogen alone raised stroke and DVT risk in the WHI; estrogen plus progestin raised pulmonary embolism, DVT, stroke and heart attack risk. Treatment is stopped right away if one occurs or is suspected and, if feasible, 4 to 6 weeks before surgery linked to clots or during long immobilization.
Endometrial, breast and ovarian cancer. Estrogen alone raises endometrial cancer risk in women with a uterus; adding a progestogen lowers hyperplasia risk. The WHI found more invasive breast cancer on estrogen plus progestin, and hormone therapy has been linked to more abnormal mammograms and to ovarian cancer.
Probable dementia. In WHIMS studies of women 65 to 79, probable dementia was more common on CE alone and on CE plus MPA than on placebo. Whether this applies to younger women is unknown.
Gallbladder, calcium and vision. Estrogens are linked to gallbladder disease needing surgery, severe high calcium in breast cancer spread to bone, and blood clots in the retina, with treatment stopped pending exam for sudden vision changes (sections 5.4 to 5.6).
Blood pressure, triglycerides, thyroid and other conditions. Estrogens can raise blood pressure in rare reactions, raise triglycerides with a risk of pancreatitis, raise thyroid hormone needs, cause fluid retention, and worsen endometriosis, hereditary angioedema, asthma, diabetes, epilepsy, migraine, porphyria, lupus and liver hemangiomas (sections 5.8 to 5.16).
From the Patient Information that comes with Minivelle:
Dose Track has a side-effect log. Each entry records the symptom, a severity (none, mild, moderate, severe or life-threatening), the date and an optional note, and can be tied to a specific dose or logged on its own. The history screen shows what you logged over time, which makes it easier to tell your prescriber when a reaction started and whether it is easing. The app records what you enter; it does not judge whether a symptom is serious. For anything on the label's call-your-doctor list, call your doctor.
This page is what the FDA label says, in plain words. It is not medical advice. Follow your prescriber, and ask them or your pharmacist about anything here.